Experiment Overview
| Repository ID: | FR-FCM-Z65F | Experiment name: | Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics | MIFlowCyt score: | 31.89% |
| Primary researcher: | Bilal Malik | PI/manager: | Bilal Malik | Uploaded by: | Bilal Malik |
| Experiment dates: | 2017-03-17 - 2022-09-17 | Dataset uploaded: | Mar 2023 | Last updated: | Mar 2023 |
| Keywords: | [immunology] [Th2] [severe asthma] | Manuscripts: | |||
| Organizations: |
University of Newcastle, University of Newcastle, Newcastle, New South Wales (Australia)
|
||||
| Purpose: | To determine the difference in group 2 innate lymphoid cells (ILC2s) between healthy and severe allergic and eosinophilic asthma (SA) participants. Furthermore, to compare the effects of mepolizumab and omalizumab on SA following treatment | ||||
| Conclusion: | ILC2s from severe allergic and eosinophilic asthma demonstrated an active phenotype typified by increased proliferation, TSLPR, GATA3 and NFATc1 expression and increased IL-5, IL-13 and IL-6 release. Mepolizumab reduced markers of ILC2s activation. | ||||
| Comments: | None | ||||
| Funding: | Not disclosed | ||||
| Quality control: | None | ||||
